Tilithromycin activity is reduced by efflux in Streptococcus pyogenes

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 4, 2005, Pages 489-495

  Cantón, Rafael ^a   Mazzariol, Annarita ^b   Morosini, María Isabel ^a   Baquero, Fernando ^a   Cornaglia, Giuseppe ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Istituto di Microbiologia   (Italy)

Author keywords

Antimicrobial resistance; Ketolides; Macrolides

Indexed keywords

ARSENATE SODIUM; BACTERIAL PROTEIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; PROTEIN ERM(B); PROTEIN MEF(A); TELITHROMYCIN; TRITIUM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ARSENIC ACID DERIVATIVE; CARRIER PROTEIN; KETOLIDE; MEFA PROTEIN, STREPTOCOCCUS; MEMBRANE PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; DRUG TRANSPORT; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; MEMBRANE TRANSPORT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; STRAIN DIFFERENCE; STREPTOCOCCUS PYOGENES; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; METABOLISM; MICROBIOLOGICAL EXAMINATION; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; ARSENATES; BACTERIAL PROTEINS; CARRIER PROTEINS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION; KETOLIDES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; STREPTOCOCCUS PYOGENES;

EID: 17444430063     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki033     Document Type: Article

References (37)

1. Bassetti, M., Mantero, E., Gatti, G. et al. (1999). Streptococcus pyogenes erythromycin resistance in Italy. Emerging Infectious Diseases 5, 302-3.
2. García-Rey, C., Aguilar, L., Baquero, F. et al. (2002). Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. Journal of Clinical Microbiology 40, 2959-63.
3. Cornaglia, G. (1999). Macrolide resistance and Streptococcus pyogenes: molecular basis, epidemiology and clinical significance. Reviews in Medical Microbiology 10, 1-14.
4. Cantón, R., Loza, E., Morosini, M. I. et al. (2002). Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. Journal of Antimicrobial Chemotherapy 50, Suppl. S1, 9-24.
5. Morosini, M. I., Cantón, R., Loza, E. et al. (2003). Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. Journal of Antimicrobial Chemotherapy 52, 50-5.
6. Felmingham, D., Feldman, C., Hryniewicz, W. et al. (2002). Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clinical Microbiology and Infection 8, Suppl. 2, 12-42.
7. Clancy, J., Petitpas, J., Dib-Hajj, F. et al. (1996). Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Molecular Microbiology 22, 867-79.
8. Santagati, M., Iannelli, F., Cascote, C. et al. (2003). The novel conjugative transposon tn1207.3 carries the macrolide efflux gene mef (A) in Streptococcus pyogenes. Microbial Drug Resistance 9, 243-7.
9. Malbruny, B., Nagai, K., Coquemont, M. et al. (2002). Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. Journal of Antimicrobial Chemotherapy 49, 935-9.
10. Bingen, E., Leclercq, R., Fitoussi, F. et al. (2002). Emergence of group A streptococcus strains with different mechanisms of macrolide resistance. Antimicrobial Agents and Chemotherapy 46, 1199-1203.
11. Bryskier, A. (2000). Ketolides-telithromycin, an example of a new class of antibacterial agents. Clinical Microbiology and Infection 6, 661-9.
12. Nord, C. E., Farrell, D. J. & Leclercq, R. (2004). Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections. Microbial Drug Resistance 10 255-63.
13. Bemer-Melchior, P., Juvin, M. E., Tassin, S. et al. (2000). In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrobial Agents and Chemotherapy 44, 2999-3002.
14. Daly, M. M., Doktor, S., Flamm, R. et al. (2004). Characterization and prevalence of mef (A), mef (E), and the associated msr (D) gene in Streptococcus pneumoniae. Journal of Clinical Microbiology 42, 3570-4.
15. Ross, J. I., Eady, E. A., Cove, J. H. et al. (1990). Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Molecular Microbiology 4, 1207-14.
16. National Committee for Clinical Laboratory Standards. (2004). Peformance Standards for Antimicrobial Susceptibility Testing - Fourteenth Informational Supplement. Approved Standard M100-S14. NCCLS, Wayne, PA, USA.
17. Soussy, C. J., Carret, G., Cavallo, J. D. et al. (2000). Antibiogram Committee of the French Microbiology Society. Report 2000-2001. Pathologie Biologie (Paris) 48, 832-71.
18. Sutcliffe, J., Tait-Kamradt, A. & Wondrack, L. (1996). Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrobial Agents and Chemotherapy 40, 1817-24.
19. Del Grosso, M., Iannelli, F., Messina, C. et al. (2002). Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. Journal of Clinical Microbiology 40, 774-8.
20. Shackcloth, J., Williams, L. & Farrell, D. J. (2004). Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromycin versus comparators. Journal of Infection 48, 229-35.
21. Bozdogan, B., Appelbaum, P. C., Kelly, L. M. et al. (2003). Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and Eastern Europe. Clinical Microbiology and Infection 9, 741-5.
22. Bingen, E., Bidet, P., Mihaila-Amrouche, L. et al. (2004). Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrobial Agents and Chemotherapy 48, 3559-62.
23. Hsueh, P. R., Teng, L. J., Lee, C. M. et al. (2003). Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data. Antimicrobial Agents and Chemotherapy 47, 2152-7.
24. Szczypa, K., Sadowy, E., Izdebski, R. et al. (2004). Rapid increase in macrolide resistance in Streptococcus pyogenes isolated in Poland during 1996-2002. Journal of Antimicrobial Chemotherapy 54, 828-31.
25. Jalava, J., Vaara, M. & Huovinen, P. (2004). Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes. Annals of Clinical Microbiology and Antimicrobials 3, 5. http://www.ann-clinmicrob.com/content/3/1/5.
26. Betriu, C., Culebras, E., Redondo, M. et al. (2002). Prevalence of macrolide and tetracycline resistance mechanism in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin. Journal of Antimicrobial Chemotherapy 50, 436-38.
27. Seppala, H., Haanpera, M., Al-Juhaish, M. et al. (2003). Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. Journal of Antimicrobial Chemotherapy 52, 636-44.
28. Morosini, M. I., Cantón, R., Loza, E. et al. (2001). In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance determinants. Antimicrobial Agents and Chemotherapy 45, 2427-31.
29. Chollet, R., Chevalier, J., Bryskier, A. et al. (2004). The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrobial Agents and Chemotherapy 48, 3621-4.
30. Sánchez, L., Pan, W., Vinas, M. et al. (1997). The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. Journal of Bacteriology 179 6855-7.
31. Clancy, J., Dib-Hajj, F., Petitpas, J. W. et al. (1997). Cloning and characterization of a novel macrolide efflux gene, mreA, from Streptococcus agalactiae. Antimicrobial Agents and Chemotherapy 41, 2719-23.
32. Matsuoka, M., Janosi, L., Endou, K. et al. (1999). Cloning and sequence of inducible and constitutive macrolide resistance gene in Staphylococcus aureus that correspond to an ABC transporter. FEMS Microbiology Letters 181, 91-100.
33. Iannelli, F., Messina, C., Santagati, M. et al. (2004). Type M resistance to macrolides in streptococci is not due to the mef A) gene, but to mat(A) encoding an ATP-dependant efflux pump. In Program and Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract C1-1188, p. 78. American Society for Microbiology, Washington, DC, USA.
34. Giovanetti, E., Brenciani, A., Burioni, R. et al. (2002). A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes. Antimicrobial Agents and Chemotherapy 46, 3750-5.
35. Douthwaite, S., Hansen, L. H. & Mauvais, P. (2000). Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Molecular Microbiology 36, 183-93.
36. Reinert, R. R., Farnken, C., van der Linden, M. et al. (2004). Molecular characterization of macrolide resistance mechanisms of Streptococcus pneumoniae and Streptococcus pyogenes isolated in Germany (2002-3003). International Journal of Antimicrobial Agents 24, 43-7.
37. Farrell, D. J., Morrissey, I., Bakker, S. et al. (2004). Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. Journal of Clinical Microbiology 42, 764-8.